Inipharm Initiates Dosing in Ph 1 Study of Small Molecule Inhibitor of HSD17B13
SEATTLE & SAN DIEGO--(BUSINESS WIRE)--Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, today announced that data on its development candidate INI-822, a small molecule inhibitor of HSD17B13, demonstrated improvements in key markers of liver homeostasis in rats fed a high fat choline-deficient diet. The data will be presented at the European Association for the Study of the Liver’s EASL Congress 2023, taking place June 21-24, 2023.
BELLEVUE, Wash. & SAN DIEGO--(BUSINESS WIRE)--Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, today announced that data on its development candidate INI-822, an inhibitor of HSD17B13, will be presented at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting®, taking place November 4-8, 2022. INI-822 demonstrated anti-fibrotic activity in the human liver cell based “liver-on-a-chip” model of NASH and led to changes in bioactive lipids in Zucker obese rats.
BELLEVUE, Wash. & SAN DIEGO--(BUSINESS WIRE)--Inipharm, a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases, today announced that it has appointed Chuhan Chung, M.D., as the company’s chief medical officer. Inipharm will also be presenting preclinical data on one of its small molecule HSD17B13 inhibitors at the International Liver Congress™ 2022, occurring in London.